AbbVie (NYSE:ABBV) Stock Rating Upgraded by Bank of America

AbbVie (NYSE:ABBV) was upgraded by equities research analysts at Bank of America from a “neutral” rating to a “buy” rating in a research report issued to clients and investors on Thursday, MarketBeat Ratings reports. The firm presently has a $234.00 target price on the stock. Bank of America‘s price target indicates a potential upside of 13.25% from the company’s current price.

Several other research analysts have also recently issued reports on ABBV. Barclays began coverage on AbbVie in a research report on Thursday, February 19th. They set an “overweight” rating and a $275.00 price objective for the company. Canaccord Genuity Group began coverage on AbbVie in a research report on Monday, April 20th. They set a “buy” rating and a $262.00 price objective for the company. Evercore lowered their price objective on AbbVie from $232.00 to $228.00 and set an “outperform” rating for the company in a research report on Wednesday, February 4th. BMO Capital Markets reaffirmed an “outperform” rating on shares of AbbVie in a research report on Monday, March 9th. Finally, Piper Sandler lowered their price objective on AbbVie from $299.00 to $294.00 and set an “overweight” rating for the company in a research report on Thursday, April 23rd. Two analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and eight have issued a Hold rating to the company’s stock. According to data from MarketBeat, AbbVie currently has an average rating of “Moderate Buy” and a consensus price target of $252.90.

AbbVie Price Performance

ABBV opened at $206.63 on Thursday. AbbVie has a 12 month low of $176.57 and a 12 month high of $244.81. The stock has a market capitalization of $365.36 billion, a price-to-earnings ratio of 101.79, a PEG ratio of 0.76 and a beta of 0.38. The business has a fifty day moving average price of $214.55 and a 200 day moving average price of $221.60.

AbbVie (NYSE:ABBV) last released its earnings results on Wednesday, April 29th. The company reported $2.65 EPS for the quarter, topping the consensus estimate of $2.59 by $0.06. The firm had revenue of $15 billion during the quarter, compared to analysts’ expectations of $14.72 billion. AbbVie had a negative return on equity of 911.57% and a net margin of 5.79%.AbbVie’s revenue for the quarter was up 12.4% on a year-over-year basis. During the same period in the previous year, the firm posted $2.46 EPS. On average, research analysts anticipate that AbbVie will post 14.21 earnings per share for the current year.

Insider Activity at AbbVie

In other AbbVie news, EVP Perry C. Siatis sold 22,381 shares of the business’s stock in a transaction that occurred on Wednesday, February 25th. The stock was sold at an average price of $230.00, for a total transaction of $5,147,630.00. Following the transaction, the executive vice president owned 38,137 shares in the company, valued at approximately $8,771,510. The trade was a 36.98% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, SVP David Ryan Purdue sold 5,230 shares of the business’s stock in a transaction that occurred on Wednesday, March 4th. The stock was sold at an average price of $233.56, for a total value of $1,221,518.80. Following the transaction, the senior vice president owned 2,654 shares in the company, valued at $619,868.24. The trade was a 66.34% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 0.06% of the company’s stock.

Institutional Investors Weigh In On AbbVie

Several institutional investors have recently made changes to their positions in the stock. Chelsea Counsel Co. purchased a new position in shares of AbbVie in the 3rd quarter valued at about $26,000. Litman Gregory Wealth Management LLC purchased a new position in shares of AbbVie in the 4th quarter valued at about $28,000. Westend Capital Management LLC purchased a new position in shares of AbbVie in the 4th quarter valued at about $29,000. Imprint Wealth LLC increased its holdings in shares of AbbVie by 56.3% in the 4th quarter. Imprint Wealth LLC now owns 125 shares of the company’s stock valued at $29,000 after purchasing an additional 45 shares in the last quarter. Finally, Texas Capital Bancshares Inc TX purchased a new position in shares of AbbVie in the 3rd quarter valued at about $31,000. 70.23% of the stock is currently owned by hedge funds and other institutional investors.

Key Headlines Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Q1 earnings beat and guidance lift — AbbVie topped Q1 estimates, raised its 2026 outlook and said immunology drugs (Skyrizi, Rinvoq) are offsetting Humira declines. This is the core positive catalyst supporting analyst upgrades. Seeking Alpha: AbbVie hikes 2026 outlook BioSpace: AbbVie tops Q1, raises outlook
• Positive Sentiment: Sell‑side upgrades and higher price targets — Multiple firms raised ratings/targets after the results (Morgan Stanley to $278, Canaccord to $265, Guggenheim reaffirm/ $249 PT, Bank of America upgraded to Buy/$234, Cantor reiterated Overweight/$240). These lifts signal renewed analyst conviction in AbbVie’s post‑Humira pivot. Benzinga: analyst moves InsiderMonkey: BofA upgrade
• Positive Sentiment: Skyrizi competitive defense — AbbVie outlined how Skyrizi will respond to new J&J plaque‑psoriasis rival Icotyde, reinforcing confidence in market share retention for a key growth driver. FiercePharma: Skyrizi defense
• Neutral Sentiment: Corporate R&D/community engagement — AbbVie awarded the AbbVie Biotech Innovators prize to RIME Therapeutics (Quebec), signalling long‑term commitment to immunology innovation, but limited near‑term financial impact. GlobeNewswire: RIME award
• Negative Sentiment: Investors remain jittery despite the beat — WSJ coverage and market commentary highlight that, while results were strong, concerns over Humira erosion, execution risk on acquisitions/pipeline strategy, and valuation keep sentiment cautious and likely drove selling pressure. YouTube/WSJ: Investors still worried
• Negative Sentiment: Pipeline trimming and insider selling — The company discontinued a cancer candidate (noted in Q1 coverage) and recent disclosures show insiders sold shares, which can weigh on near‑term sentiment. BioSpace: discontinued candidate
• Negative Sentiment: Small analyst estimate cuts and mixed institutional flows — Erste trimmed FY2026/27 EPS modestly; recent large institutional portfolio shifts (some big sellers) add uncertainty to demand. These are headwinds for the stock near term. MarketBeat: analyst/flows summary

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.